Epigral Ltd
Epigral Q2 Results 2026 (FY27): Revenue ₹752 Cr, PAT ₹64 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #28 of 68 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Epigral Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Revenue: ₹752 Crore, up 28% YoY from ₹589 Crore in Q2FY26.
As stated in Epigral Ltd's Q2 FY27 investor presentation · published 2 Nov 2026. Reported figures, not investment advice.
Based on Epigral Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Revenue: ₹752 Crore, up 28% YoY from ₹589 Crore in Q2FY26 (Page 16, 5) - Q2FY27 Sales volume grew by 6% YoY despite challenging conditions (Page 5) - H1FY27 Revenue: ₹1,461 Crore, up 21% Yo Q2FY27 EBITDA: ₹136 Crore, up 3% YoY from ₹132 Crore - Q2FY27 EBITDA Margin: 18%, down from 23% in Q2FY26 (margin muted due to high raw material costs) - Q2FY27 PAT: ₹64 Crore, up 26% Yo
From Epigral Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
How did Epigral's revenue grow in the September 2026 quarter?
- Q2FY27 Revenue: ₹752 Crore, up 28% YoY from ₹589 Crore in Q2FY26 (Page 16, 5)
- Q2FY27 Sales volume grew by 6% YoY despite challenging conditions (Page 5)
- H1FY27 Revenue: ₹1,461 Crore, up 21% YoY from ₹1,204 Crore in H1FY26 (Page 9)
- Derivatives & Specialty business revenue contribution increased to 57% in Q2FY27 from 50% in Q2FY26 (Page 5)
2 more points from Epigral Ltd's call on revenue
Create a free account to keep reading this call
What happened to Epigral's margins in Q2 FY27?
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
What capex is Epigral planning?
- CPVC Resin Expansion: Additional 75,000 TPA capacity; total 150,000 TPA (world’s largest); expected commissioning Q3FY27.
- Epichlorohydrin (ECH) Expansion: Additional 50,000 TPA capacity; total 100,000 TPA (India’s largest); expected commissioning Q3FY27.
- Epoxy Resin & Formulations Plant: Capacity 125,000 TPA; location existing Dahej complex; expected commissioning H2FY28.
- Multi-Purpose Plant (MPP): Downstream of Epichlorohydrin and Chlorotoluenes, located at existing complex; expected commissioning H2FY28.
- Wind Solar Hybrid Power Plant: Additional 19.80 MW; expected commissioning Q3FY27.
2 more points from Epigral Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Epigral raising money or cutting debt?
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Epigral's order book?
See what Epigral Ltd said on order book & pipeline — free account, 30 seconds.
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neptune Petrochemicals (Q2 FY27)
295.72 Lakhs, increased by 21% year-on-year. Key results statement takeaways from Neptune Petrochemicals Ltd's Q2 FY27 results statement — and how it ranks agai
- Arvee Laboratories (India) (Q2 FY27)
Revenue from Operations for the quarter ended September 30, 2026, is ₹2,492.81 Lakhs (Page 5). Key results statement takeaways from Arvee Laboratories (India) L
- DIC India (Q2 FY27)
Revenue from sale of goods: ₹27,303.98 million . Key results statement takeaways from DIC India Ltd's Q2 FY27 results statement — and how it ranks against secto
- Linde India (Q2 FY27)
EBITDA: ₹1,887 million (though page 6 shows ₹1,881.54M) . Key results statement takeaways from Linde India Ltd's Q2 FY27 results statement — and how it ranks ag
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Epigral Ltd Q2 FY27 results?
Q2FY27 Revenue: ₹752 Crore, up 28% YoY from ₹589 Crore in Q2FY26 (Page 16, 5) - Q2FY27 Sales volume grew by 6% YoY despite challenging conditions (Page 5) - H1FY27 Revenue: ₹1,461 Crore, up 21% Yo Q2FY27 EBITDA: ₹136 Crore, up 3% YoY from ₹132 Crore - Q2FY27 EBITDA Margin: 18%, down from 23% in Q2FY26 (margin muted due to high raw material costs) - Q2FY27 PAT: ₹64 Crore, up 26% Yo
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 13.9 with a market cap of ₹3,773 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
CPVC Resin Expansion: Additional 75,000 TPA capacity; total 150,000 TPA (world’s largest); expected commissioning Q3FY27.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.